Protalix BioTherapeutics
PLX
PLX
34 hedge funds and large institutions have $5.61M invested in Protalix BioTherapeutics in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
26% less capital invested
Capital invested by funds: $7.58M → $5.61M (-$1.97M)
Holders
34
Holding in Top 10
–
Calls
$1.57M
Puts
$1.42M
Top Buyers
| 1 | +$563K | |
| 2 | +$339K | |
| 3 | +$57.8K | |
| 4 |
IWM
IHT Wealth Management
Chicago,
Illinois
|
+$44K |
| 5 |
DC
Davenport & Co
Richmond,
Virginia
|
+$32K |
Top Sellers
| 1 | -$444K | |
| 2 | -$124K | |
| 3 | -$72K | |
| 4 |
Renaissance Technologies
New York
|
-$57K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$45.7K |